PTO/SB/08a (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Sperwork Reduction of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for to HOE WAS TO

Sheet

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/563,310			
Filing Date	May 12, 2006			
First Named Inventor	Jörgen Carlsson et al.			
Art Unit	1645			
Examiner Name	Swartz, Rodney P.			
Attorney Docket Number	102821-202	フ		

			U. S. PATENT D			
Examiner Ci		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ^{2 (# known)}			Figures Appear	
		US-				
		US-		-		
		US-				
		US-				
		US-		1		
		US-				
		US-		*		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		· · · · · · · · · · · · · · · · · · ·		
		US-	1.			
		US-	T			
		US-				
· · · · ·		US-				
		US-			,	
		US-				

		FORE	IGN PATENT DOCL	JMENTS		
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ'
	1.	WO 89/06692 A1	07-27-1989	Hudziak, Robert M. et al.		
	2.	WO 01/77342 A1	10-18-2001	Miller, Kathy L. et al.		
		·				
	· .					

Examiner.	,		Date	
Signature ·		Ŷ	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 03/31/2009, OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date			Complete if Known				
STATEMENT BY APPLICANT First Named Inventor Art Unit 1645 Examiner Name Swartz, Rodney P. Attorney Docket No. NON PATENT LITERATURE DOCUMENTS EXAMINER No. EXAMINER No. S. SLAMON, M.D., Ph.D., DENNIS J. ET AL., "Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 344, No. 11, Pages 783-792 (March 15, 2001).			Application Numb	er	10/563,310		
Sheet 2 of 2 NON PATENT LITERATURE DOCUMENTS EXAMINER INTITAL* 3. SLAMON, M.D., Ph.D., DENNIS J. ET AL., "Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 344, No. 111, Pages 783-792 (March 15, 2001).			Filing Date		May 12, 2006		
Examiner Name Swartz, Rodney P.			First Named Inven	tor	Jörgen Carlsson et al.	·	
Sheet 2 of 2 NON PATENT LITERATURE DOCUMENTS EXAMINER INITIAL* Cite No. SLAMON, M.D., Ph.D., DENNIS J. ET AL., "Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 344, No. 11, Pages 783-792 (March 15, 2001).			15	Art Unit		1645	
NON PATENT LITERATURE DOCUMENTS EXAMINER INITIAL* Cite No. SLAMON, M.D., Ph.D., DENNIS J. ET AL., "Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 344, No. 11, Pages 783-792 (March 15, 2001).				Examiner Name		Swartz, Rodney P.	
EXAMINER INITIAL* Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published 3. SLAMON, M.D., Ph.D., DENNIS J. ET AL., "Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 344, No. 11, Pages 783-792 (March 15, 2001).	Sheet	2 о	f 2	Attorney Docket N	lo.	102821-202	
No. of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published 3. SLAMON, M.D., Ph.D., DENNIS J. ET AL., "Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 344, No. 11, Pages 783-792 (March 15, 2001).	•		NON PATEN	T LITERATURE	DOCUMENTS		.
Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 344, No. 11, Pages 783-792 (March 15, 2001).	INITIAL * No. of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city						· T ²
		3.	Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 344, No.				
					· · · · · · · · · · · · · · · · · · ·		
					•		
			•				
Examiner Date	Examiner				Date		
Signature: Considered	Signature:				Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.